Federation des caisses Desjardins du Quebec’s Pyxis Oncology PYXS Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.5K	Buy	+4,500	New	+$8.6K	﹤0.01%	2309

Other funds holding PYXS

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's PYXS Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Pyxis Oncology (PYXS) in Q2 2026: 4,500 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #2309 among its holdings.

76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

Federation des caisses Desjardins du Quebec held 4,500 shares of Pyxis Oncology worth $13.5K as of Q2 2026.
Pyxis Oncology was a new Federation des caisses Desjardins du Quebec position in Q2 2026.
Pyxis Oncology made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2309 holding.
76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.